Advisory Council for the Elimination of Tuberculosis (ACET), 67459 [2011-28219]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 211 / Tuesday, November 1, 2011 / Notices
Dated: October 25, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
Dated: October 25, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2011–28221 Filed 10–31–11; 8:45 am]
[FR Doc. 2011–28219 Filed 10–31–11; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Food and Drug Administration
Advisory Council for the Elimination of
Tuberculosis (ACET)
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Survey of ‘‘Health
Care Providers’ Responses to Medical
Device Labeling’’
[Docket No. FDA–2011–N–0766]
srobinson on DSK4SPTVN1PROD with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee:
Times and Dates:
8:30 a.m.–5:30 p.m., December 6, 2011.
8:30 a.m.–2:30 p.m., December 7, 2011.
Place: Corporate Square, Building 8, 1st
Floor Conference Room, Atlanta, Georgia
30333, telephone (404) 639–8317.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 100 people.
Purpose: This council advises and makes
recommendations to the Secretary of Health
and Human Services, the Assistant Secretary
for Health, and the Director, CDC, regarding
the elimination of tuberculosis. Specifically,
the Council makes recommendations
regarding policies, strategies, objectives, and
priorities; addresses the development and
application of new technologies; and reviews
the extent to which progress has been made
toward eliminating tuberculosis.
Matters to be Discussed: Agenda items
include issues pertaining to the future
directions of tuberculosis control and
elimination in the United States: (1) STOP
TB USA; (2) Institute of Medicine Report;
and (3) The Restructuring of United States
Tuberculosis Program (TRUST); Update on
ACET Workgroups; and other related
tuberculosis issues.
Agenda items are subject to change as
priorities dictate.
Contact Person For More Information:
Margie Scott-Cseh, Centers for Disease
Control and Prevention, 1600 Clifton Road
NE., M/S E–07, Atlanta, Georgia 30333,
telephone (404) 639–8317.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register Notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
VerDate Mar<15>2010
17:04 Oct 31, 2011
Jkt 226001
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
this proposed information collection
‘‘Health Care Providers’ Responses to
Medical Device Labeling.’’
DATES: Submit either electronic or
written comments on the collection of
information by January 3, 2012.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, (301) 796–
5156, Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
SUMMARY:
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
67459
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Survey of ‘‘Health Care Providers’
Responses to Medical Device
Labeling’’—21 CFR Part 801 (OMB
Control Number 0910–New)
The purpose of this study is to
determine the most effective device
labeling format and inform an FDA’s
regulatory approach on standardized
device labeling. Building upon the
research methodology and success of
the approach FDA used to evaluate drug
labeling, we propose to ask health care
providers (HCPs) to evaluate the quality
of labeling (e.g. instructions for use,
directions) for a medical device and to
report the degree to which they could
follow those instructions, how useful
the information is, and how well
organized the information is. This work
will allow FDA to assess whether HCPs
find the format and content of device
labeling clear, understandable, useful,
and user-friendly. Findings will provide
evidence to inform FDA’s regulatory
approach to standardizing medical
device labeling across the United States.
FDA estimates the burden of this
collection of information as follows:
E:\FR\FM\01NON1.SGM
01NON1
]]>Agencies
[Federal Register Volume 76, Number 211 (Tuesday, November 1, 2011)]
[Notices]
[Page 67459]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-28219]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Council for the Elimination of Tuberculosis (ACET)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting of the aforementioned
committee:
Times and Dates:
8:30 a.m.-5:30 p.m., December 6, 2011.
8:30 a.m.-2:30 p.m., December 7, 2011.
Place: Corporate Square, Building 8, 1st Floor Conference Room,
Atlanta, Georgia 30333, telephone (404) 639-8317.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 100 people.
Purpose: This council advises and makes recommendations to the
Secretary of Health and Human Services, the Assistant Secretary for
Health, and the Director, CDC, regarding the elimination of
tuberculosis. Specifically, the Council makes recommendations
regarding policies, strategies, objectives, and priorities;
addresses the development and application of new technologies; and
reviews the extent to which progress has been made toward
eliminating tuberculosis.
Matters to be Discussed: Agenda items include issues pertaining
to the future directions of tuberculosis control and elimination in
the United States: (1) STOP TB USA; (2) Institute of Medicine
Report; and (3) The Restructuring of United States Tuberculosis
Program (TRUST); Update on ACET Workgroups; and other related
tuberculosis issues.
Agenda items are subject to change as priorities dictate.
Contact Person For More Information: Margie Scott-Cseh, Centers
for Disease Control and Prevention, 1600 Clifton Road NE., M/S E-07,
Atlanta, Georgia 30333, telephone (404) 639-8317.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Dated: October 25, 2011.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2011-28219 Filed 10-31-11; 8:45 am]
BILLING CODE 4163-18-P
